The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans*
- 15 September 1996
- journal article
- clinical trial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 60 (3) , 295-307
- https://doi.org/10.1016/s0009-9236(96)90056-9
Abstract
OBJECTIVES: We studied the disposition of dextromethorphan in extensive and poor metabolizer subjects, as well as the effect of this polymorphism on the antitussive action of dextromethorphan. METHODS: Six extensive metabolizers were studied on four occasions: (1) after 30 mg dextromethorphan, (2) after 30 mg dextromethorphan 1 hour before 50 mg quinidine, (3) after placebo, and (4) after 50 mg quinidine. Six poor metabolizers were studied on two occasions: (1) after 30 mg dextromethorphan and (2) after placebo. Blood and urine were collected over 168 hours and assayed for dextromethorphan, total (conjugated and unconjugated) dextrorphan, 3-methoxymorphinan, and total 3-hydroxymorphinan. On each occasion at each blood sampling time, capsaicin was administered as an aerosol to provoke cough. RESULTS: Dextromethorphan area under the plasma concentration-time curve (AUC) was 150-fold greater in the poor metabolizers than in the extensive metabolizers, and quinidine increased the AUC in extensive metabolizers 43-fold. The median dextromethorphan half-life was 19.1 hours in poor metabolizers, 5.6 hours in extensive metabolizers given quinidine, and 2.4 hours in extensive metabolizers. For dextrorphan (as total), the AUC was reduced 8.6-fold in poor metabolizers; quinidine had no effect on the AUC. The median half-life was 10.1 hours in poor metabolizers, 6.6 hours in extensive metabolizers given quinidine, and 1.4 hours in extensive metabolizers. The apparent partial clearance of dextromethorphan to dextrorphan was 1.2 L/hr in poor metabolizers, 78.5 L/hr in extensive metabolizers given quinidine, and 970 L/hr in extensive metabolizers. There was a strong (r2 = 0.82) and significant (p < 0.01) positive correlation between the prestudy urinary metabolic ratios and the partial clearances of dextromethorphan to dextrorphan. There was very large intersubject variability in responsiveness to capsaicin. There was no difference in the capsaicin-induced cough frequency in the three groups. Dextromethorphan had no antitussive effect in this experimental cough model. CONCLUSION: The disposition of dextromethorphan was substantially influenced by CYP2D6 status. Capsaicin may not be an ideal agent in experimental cough studiesKeywords
This publication has 54 references indexed in Scilit:
- Dextromethorphan metabolism in rat: Interstrain differences and the fate of individually administered oxidative metabolitesXenobiotica, 1994
- Single-dose quinidine treatment inhibits mexiletine oxidation in extensive metabolizers of debrisoquineLife Sciences, 1991
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- Assessment of antitussive effects by citric acid thresholdRespiratory Medicine, 1983
- Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugsLife Sciences, 1983
- Hypotensive response to debrisoquine and hydroxylation phenotypeLife Sciences, 1978
- THE COUGH RESPONSE OF HEALTHY HUMAN SUBJECTS STIMULATED BY CITRIC ACID AEROSOLThe Lancet Healthy Longevity, 1957
- EVALUATION OF A NEW COUGH SUPPRESSANTThe Lancet Healthy Longevity, 1954
- QUANTITATIVE COMPARISON OF DEXTROMETHORPHAN HYDROBROMIDE AND CODEINEThe Lancet Healthy Longevity, 1954